Publications by authors named "J E Blakeley"
Background: Despite advances in our understanding of the molecular underpinnings of meningioma progression and innovations in systemic and local treatments, recurrent meningiomas remain a substantial therapeutic challenge. The objective of this systematic review and meta-analysis is to provide a historical baseline, contemporary analysis, and propose a "rate of probable interest" to inform future clinical trial design and development on behalf of the RANO meningioma group.
Methods: PubMed, ClinicalTrials.
Article Synopsis
- Malignant peripheral nerve sheath tumors (MPNST) pose a significant risk to patients with neurofibromatosis type 1 (NF1), with current treatments failing to improve outcomes, highlighting the need for new therapies that target the tumor's immune environment.
- Researchers examined the immune microenvironment in NF1-associated tumors, using various techniques to analyze how immune cells infiltrate and respond to these tumors.
- Results showed that malignant progression involved increased infiltration of specific immune cells, particularly tumor-associated macrophages, linked to worse patient outcomes, indicating a potential for therapies that can enhance anti-tumor immune responses.
Background: In children and adolescents/young adults (CAYA) with neurofibromatosis type I (NF1), associations between anthropometric measurements, plexiform neurofibroma (pNF) tumor volume (TV), and treatment history are unknown.
Methods: We retrospectively investigated anthropometrics in CAYA on the National Cancer Institute (NCI) NF1 Natural History Study who had pNF TV assessed by imaging (n = 106). We determined CDC height/weight percentiles and estimated Preece-Baines (PB) height growth curve parameters.
Importance: There is a burgeoning interest in therapeutic development for cutaneous neurofibromas (cNFs), a major cause of morbidity in persons with neurofibromatosis type 1 (NF1). To determine meaningful clinical trial outcomes, deeper understanding is needed regarding how cNFs are associated with quality of life (QoL). However, this understanding has been hampered by challenges in recruiting participants with this rare genetic disease.
View Article and Find Full Text PDF